Stock CLDX CELLDEX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
35.28 USD +0.48% Intraday chart for Celldex Therapeutics, Inc. +5.95% -11.04%
Jun. 05 Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing MT
Jun. 05 Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,319,156, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,298,384, According to a Recent SEC Filing
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024
Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering
Sector Update: Health Care Stocks Weaker Monday Afternoon
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates
Sector Update: Health Care Stocks Mixed Premarket Monday
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Celldex Therapeutics Prices $200.5 Million Share Offering
Celldex Shares Rise as Phase 2 Trial Shows Barzolvolimab Meets Primary Efficacy Endpoint for Chronic Spontaneous Urticaria
Sector Update: Health Care Stocks Advance Premarket Monday
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDX Stock
  4. News Celldex Therapeutics, Inc.
  5. Other languages